Hossein Borghaei, DO, MS

Next-generation sequencing provides oncologists with accurate information in a cost-effective manner, thereby affording treatment options we would not otherwise have.

During a Targeted Oncology Case-Based Roundtable event, Hossein Borghaei, DO, MS, moderated a discussion about a 59-year-old man with non–small cell lung cancer.

Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology at Fox Chase Cancer Center, discusses biomarkers that may help identify patients with lung cancer who can benefit from immunotherapy agents. Since the introduction of these agents, PD-L1 has been used as a potential biomarker for selecting patients that may benefit from treatment. As PD-L1 is not completely reliable, there is interest in developing additional biomarkers.